Announcements Trials
Browse Landscape

Phase

Phase 2 3Phase 1/2 1

Status

Terminated 1Recruiting 1Active not recruiting 1

Sponsor Class

INDUSTRY 3

Study Type

Interventional 3

Sponsor

Cancer Type

Sarcoma 1Head & Neck 1Dermatologic 1

Conditions

Sarcoma 1Salivary Gland Neoplasms 1Neoplasm Metastasis 1Melanoma 1Head and Neck Neoplasms 1Carcinoma, Squamous Cell 1

Interventions

Cisplatin 1519Carboplatin 1420Cyclophosphamide 1360Gemcitabine 1235Bevacizumab 1226Paclitaxel 1211Radiotherapy 1176Docetaxel 1080pembrolizumab 1028Oxaliplatin 936Capecitabine 901Fluorouracil 833Rituximab 729Doxorubicin 683Nivolumab 679Dexamethasone 666Etoposide 660Irinotecan 622Leucovorin 575Pemetrexed 510Drug Therapy 493Cetuximab 483Trastuzumab 469Cytarabine 466Magnetic Resonance Spectroscopy 458Filgrastim 446Prednisone 433Lenalidomide 409Specimen Handling 408Temozolomide 400

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 2 × EBC-46 × Clear all
NCT05755113 2026-03-12

A Clinical Study to Investigate the Efficacy of Intratumoral Tigilanol Tiglate in Soft Tissue Sarcoma

QBiotics Group Limited

Phase 2 Recruiting
40 enrolled
Sarcoma

Neoplasm Metastasis, Sarcoma

NCT05608876 2025-08-07

A Clinical Study to Investigate the Efficacy of Tigilanol Tiglate Directly in Head and Neck Cancer

QBiotics Group Limited

Phase 2 Active not recruiting
15 enrolled
Head & Neck

Carcinoma, Squamous Cell, Head and Neck Neoplasms, Salivary Gland Neoplasms

NCT05234437 2023-04-19

A Trial of Intratumoural Tigilanol Tiglate in Adult Participants With Stage IIIB to IV M1c Melanoma

QBiotics Group Limited

Phase 2 Terminated
1 enrolled
Dermatologic

Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡